Loxo Oncology, Inc. (NASDAQ:LOXO) major shareholder Aisling Capital Iii Lp sold 500,000 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $75.00, for a total value of $37,500,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Loxo Oncology, Inc. (NASDAQ LOXO) traded down $0.18 during trading hours on Wednesday, reaching $77.53. 355,950 shares of the company’s stock traded hands, compared to its average volume of 371,017. Loxo Oncology, Inc. has a one year low of $25.25 and a one year high of $95.92.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new position in shares of Loxo Oncology during the 3rd quarter worth approximately $122,000. Ameritas Investment Partners Inc. boosted its position in shares of Loxo Oncology by 31.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 419 shares during the period. Legal & General Group Plc boosted its position in shares of Loxo Oncology by 8.4% during the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 284 shares during the period. BNP Paribas Arbitrage SA boosted its position in Loxo Oncology by 4,388.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,194 shares during the period. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in Loxo Oncology in the 3rd quarter valued at approximately $212,000.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.